potassiumvial size availability ndc 0409-7295-11 15 ml single-dose fliptop vial ndc 63323-0086-05...
TRANSCRIPT
NOW AVAILABLE
The First FDA-ApprovedPotassium Phosphates Injectable
FIRST FDA APPROVED!FIRST FDA APPROVED!
P H A R M A
Exclusively from
P H A R M A
Exclusively from
Important Safety Information
INDICATIONS AND USAGEPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source
of phosphorus:
– in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of
age and older when oral or enteral replacement is not possible, insufficient or contraindicated.
– for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age
and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or
contraindicated.
• Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing
less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due
to the risk of aluminum toxicity.
CONTRAINDICATIONS– hyperkalemia
– hyperphosphatemia
– hypercalcemia or significant hypocalcemia
– severe renal impairment (eGFR less than 30 mL/min/1.73m2) and end stage renal disease
WARNINGS AND PRECAUTIONS– Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration:
Administer only after dilution or admixing; do not exceed the recommended infusion rate. Con-
tinuous electrocardiographic (ECG) monitoring may be needed during infusion.
– Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress
occur, stop the infusion and initiate a medical evaluation.
– Hyperkalemia: Increased risk in patients with renal impairment, severe adrenal insufficiency, or
treated with drugs that increase potassium. Patients with cardiac disease may be more suscepti-
ble. Do not exceed the maximum daily amount of potassium or the recommended infusion rate.
Continuous ECG monitoring may be needed during infusion.
– Hyperphosphatemia and Hypocalcemia: Monitor serum phosphorus and calcium concentra-
tions during and following infusion.
– Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.
– Hypomagnesemia: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor
serum magnesium concentrations during treatment.
– Vein Damage and Thrombosis: Infuse concentrated or hypertonic solutions through a central
catheter.
DRUG INTERACTIONSUse of Other Medications that Increase Potassium: Avoid use in patients receiving such products. If
use cannot be avoided, closely monitor serum potassium concentrations.
DOSAGE AND ADMINISTRATION– Administer intravenously only after dilution or admixing in a larger volume of fluid.
– POTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/
mL).
– Monitor serum phosphorus, potassium, calcium, and magnesium concentrations.
– See full prescribing information for instructions on preparation and administration.
ADVERSE REACTIONSAdverse reactions are hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia.
To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
PotassiumPHOSPHATESI N J E C T I O N
PotassiumPHOSPHATESI N J E C T I O N
Please see Full Prescribing Information in pocket for additional safety information
PPH-00012
It’s the first FDA-approved formulation available Currently, there is no other potassium phosphates injections formulation available that has been
approved by the FDA.
Market friendly price Competitively priced to ensure physicians have the choice to prescribe cost effective solutions
to their patients.
It addresses concerns from previous shortages of potassium phosphatesThe current phosphate repletion treatment market is strained due to previous shortages from
unapproved versions. Potassium Phosphates Injection helps alleviate these shortages by providing
a consistent supply of an FDA-approved formulation.
Current formulations have high aluminum contentCurrent unapproved formulations have higher aluminum content. Potassium Phosphates Injection
from CMP Pharma is a safe and consistent choice for healthcare professionals working with phosphate
replacement providing lower aluminum levels than current formulations.
Potassium Phosphates Injection is indicated as a source of phosphorus in intravenous fluids to correct
hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral
replacement is not possible, insufficient or contraindicated. Additionally, it is indicated as an additive
for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by
standard electrolyte or nutrient solutions.
CMP Potassium Phosphates Injection is now availablefrom national and regional wholesalers. For more information, contact
CMP Pharma at 252-753-7111.
Why Potassium Phosphates Injection from CMP Pharma?
FDA Approved
Low Price
Lower Aluminum
Consistent Supply
Inside right (full spread) Inside right (2-panel spread) Outside frontOutside back
See page 5 for Important Safety Information
NOW AVAILABLE
The First FDA-ApprovedPotassium Phosphates Injectable
FIRST FDA APPROVED!FIRST FDA APPROVED!
P H A R M A
Exclusively from
P H A R M A
Exclusively from
Important Safety Information
INDICATIONS AND USAGEPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source
of phosphorus:
– in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of
age and older when oral or enteral replacement is not possible, insufficient or contraindicated.
– for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age
and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or
contraindicated.
• Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing
less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due
to the risk of aluminum toxicity.
CONTRAINDICATIONS– hyperkalemia
– hyperphosphatemia
– hypercalcemia or significant hypocalcemia
– severe renal impairment (eGFR less than 30 mL/min/1.73m2) and end stage renal disease
WARNINGS AND PRECAUTIONS– Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration:
Administer only after dilution or admixing; do not exceed the recommended infusion rate. Con-
tinuous electrocardiographic (ECG) monitoring may be needed during infusion.
– Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress
occur, stop the infusion and initiate a medical evaluation.
– Hyperkalemia: Increased risk in patients with renal impairment, severe adrenal insufficiency, or
treated with drugs that increase potassium. Patients with cardiac disease may be more suscepti-
ble. Do not exceed the maximum daily amount of potassium or the recommended infusion rate.
Continuous ECG monitoring may be needed during infusion.
– Hyperphosphatemia and Hypocalcemia: Monitor serum phosphorus and calcium concentra-
tions during and following infusion.
– Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.
– Hypomagnesemia: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor
serum magnesium concentrations during treatment.
– Vein Damage and Thrombosis: Infuse concentrated or hypertonic solutions through a central
catheter.
DRUG INTERACTIONSUse of Other Medications that Increase Potassium: Avoid use in patients receiving such products. If
use cannot be avoided, closely monitor serum potassium concentrations.
DOSAGE AND ADMINISTRATION– Administer intravenously only after dilution or admixing in a larger volume of fluid.
– POTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/
mL).
– Monitor serum phosphorus, potassium, calcium, and magnesium concentrations.
– See full prescribing information for instructions on preparation and administration.
ADVERSE REACTIONSAdverse reactions are hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia.
To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
PotassiumPHOSPHATESI N J E C T I O N
PotassiumPHOSPHATESI N J E C T I O N
Please see Full Prescribing Information in pocket for additional safety information
PPH-00001
It’s the first FDA-approved formulation available Currently, there is no other potassium phosphates injections formulation available that has been
approved by the FDA.
Market friendly price Competitively priced to ensure physicians have the choice to prescribe cost effective solutions
to their patients.
It addresses concerns from previous shortages of potassium phosphatesThe current phosphate repletion treatment market is strained due to previous shortages from
unapproved versions. Potassium Phosphates Injection helps alleviate these shortages by providing
a consistent supply of an FDA-approved formulation.
Current formulations have high aluminum contentCurrent unapproved formulations have higher aluminum content. Potassium Phosphates Injection
from CMP Pharma is a safe and consistent choice for healthcare professionals working with phosphate
replacement providing lower aluminum levels than current formulations.
Potassium Phosphates Injection is indicated as a source of phosphorus in intravenous fluids to correct
hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral
replacement is not possible, insufficient or contraindicated. Additionally, it is indicated as an additive
for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by
standard electrolyte or nutrient solutions.
CMP Potassium Phosphates Injection is now availablefrom national and regional wholesalers. For more information, contact
CMP Pharma at 252-753-7111.
Why Potassium Phosphates Injection from CMP Pharma?
FDA Approved
Low Price
Lower Aluminum
Consistent Supply
Inside right (full spread) Inside right (2-panel spread) Outside frontOutside back
See page 5 for Important Safety Information
Aluminum Toxicity
Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impair-
ment. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature,
and they require large amounts of calcium and phosphate solutions, which also contain aluminum.
Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day
of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and
bone toxicity. Tissue loading may occur at even lower rates of administration. This product contains no
more than 15,000 mcg/L of aluminum.
P H A R M A
Exclusively from
PotassiumPHOSPHATESI N J E C T I O N
CMP Potassium Phosphates Injection is now available from
national and regional wholesalers. For more information, contact
CMP Pharma at 252-753-7111.
Potassium Phosphates Injection, USP–Pfizer Hospira*
Potassium Phosphates Injection, USP–Fresenius Kabi*
Potassium Phosphates Injection–CMP Pharma
US Approval Status
Not FDA Approved Not FDA Approved FDA Approved
Dosage Forms and Strengths
POTASSIUM PHOSPHATES
Injection, USP
45 mM P (3 mM P/mL
Potassium 4.4 mEq K+/mL
POTASSIUM PHOSPHATES
INJECTION, USP
3 mmol Phosphorus/mL and
4.4 mmol Potassium/mL 4.4
mEq Potassium/mL
POTASSIUM PHOSPHATES
Injection
45 mM P (3 mM P/mL)
Potassium 4.7 mEq K+/mL
Indications and Usage
Potassium Phosphates
Injection, USP, 3 mM P/mL is
indicated as a source of
phosphorus, for addition to
large volume intravenous
fluids, to prevent or correct
hypophosphatemia in
patients with restricted or no
oral intake. It is also useful
as an additive for preparing
specific intravenous fluid
formulas when the needs of
the patient cannot be met by
standard electrolyte or nutrient
solutions. The concomitant
amount of potassium (K+ 4.4
mEq/mL) must be calculated
into total electrolyte dose of
such prepared solutions.
Potassium Phosphates
Injection, USP (3 mmol/mL), is
indicated as a source of
phosphate, for addition to
large volume intravenous fluids
to prevent or correct
hypophosphatemia in patients
with restricted or no oral
intake. It is also useful as an
additive for preparing specific
intravenous fluid formulas
when the needs of the patient
cannot be met by standard
electrolyte or nutrient
solutions.
POTASSIUM PHOSPHATES
INJECTION is a phosphorus
replacement product indicated
as a source of phosphorus in
intravenous fluids to correct
hypophosphatemia in adults
and pediatric patients 12 years
of age and older when oral
or enteral replacement is not
possible, insufficient or
contraindicated and for
parenteral nutrition in adults
weighing at least 45 kg and
pediatric patients 12 years of
age and older weighing at least
40 kg when oral or enteral
nutrition is not possible,
insufficient or contraindicated.
Vial Size Availability
NDC 0409-7295-11
15 mL Single-dose Fliptop Vial
NDC 63323-0086-05 5mL
NDC 63323-0086-15 15mL
NDC 63323-0086-50 50mL
NDC 46287-024-15
15 mL single-dose glass vial
Aluminum Toxicity
Contains no more than
31,000 mcg/L.
Contains no more than
32,800 mcg/L of aluminum.
This product contains no
more than 15,000 mcg/L of
aluminum.
Storage Store at 20 to 25°C
(68 to 77°F).
Store between 15 and 30°C. Store at 2°C to 8°C (36°F to
46°F); After dilution, the solu-
tion is stable for 48 hours
under refrigeration at 2°C to
8°C (36°F to 46°F) or at room
temperature from 20°C to
25°C (68°F to 77°F)
WAC Price 15 mL $14.57 5 mL $14.8115 mL $30.2850 mL $67.27
15 mL $13.10
* All trademarks mentioned herein are the exclusive property of their respective owners.
FDA Approved
Low Price
Lower Aluminum
Consistent Supply
short lip glues here
short lip glues here
Inside centerInside left
Pocket folds over to glue on this side
Inside pocket back
Inside pocket front
Insert 1Trim size: 8 x 5.25
Flat Size: TBD—
(Do Not Hold Die-line)
See page 5 for Important Safety Information
Aluminum Toxicity
Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impair-
ment. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature,
and they require large amounts of calcium and phosphate solutions, which also contain aluminum.
Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day
of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and
bone toxicity. Tissue loading may occur at even lower rates of administration. This product contains no
more than 15,000 mcg/L of aluminum.
P H A R M A
Exclusively from
PotassiumPHOSPHATESI N J E C T I O N
CMP Potassium Phosphates Injection is now available from
national and regional wholesalers. For more information, contact
CMP Pharma at 252-753-7111.
Potassium Phosphates Injection, USP–Pfizer Hospira*
Potassium Phosphates Injection, USP–Fresenius Kabi*
Potassium Phosphates Injection–CMP Pharma
US Approval Status
Not FDA Approved Not FDA Approved FDA Approved
Dosage Forms and Strengths
POTASSIUM PHOSPHATES
Injection, USP
45 mM P (3 mM P/mL
Potassium 4.4 mEq K+/mL
POTASSIUM PHOSPHATES
INJECTION, USP
3 mmol Phosphorus/mL and
4.4 mmol Potassium/mL 4.4
mEq Potassium/mL
POTASSIUM PHOSPHATES
Injection
45 mM P (3 mM P/mL)
Potassium 4.7 mEq K+/mL
Indications and Usage
Potassium Phosphates
Injection, USP, 3 mM P/mL is
indicated as a source of
phosphorus, for addition to
large volume intravenous
fluids, to prevent or correct
hypophosphatemia in
patients with restricted or no
oral intake. It is also useful
as an additive for preparing
specific intravenous fluid
formulas when the needs of
the patient cannot be met by
standard electrolyte or nutrient
solutions. The concomitant
amount of potassium (K+ 4.4
mEq/mL) must be calculated
into total electrolyte dose of
such prepared solutions.
Potassium Phosphates
Injection, USP (3 mmol/mL), is
indicated as a source of
phosphate, for addition to
large volume intravenous fluids
to prevent or correct
hypophosphatemia in patients
with restricted or no oral
intake. It is also useful as an
additive for preparing specific
intravenous fluid formulas
when the needs of the patient
cannot be met by standard
electrolyte or nutrient
solutions.
POTASSIUM PHOSPHATES
INJECTION is a phosphorus
replacement product indicated
as a source of phosphorus in
intravenous fluids to correct
hypophosphatemia in adults
and pediatric patients 12 years
of age and older when oral
or enteral replacement is not
possible, insufficient or
contraindicated and for
parenteral nutrition in adults
weighing at least 45 kg and
pediatric patients 12 years of
age and older weighing at least
40 kg when oral or enteral
nutrition is not possible,
insufficient or contraindicated.
Vial Size Availability
NDC 0409-7295-11
15 mL Single-dose Fliptop Vial
NDC 63323-0086-05 5mL
NDC 63323-0086-15 15mL
NDC 63323-0086-50 50mL
NDC 46287-024-15
15 mL single-dose glass vial
Aluminum Toxicity
Contains no more than
31,000 mcg/L.
Contains no more than
32,800 mcg/L of aluminum.
This product contains no
more than 15,000 mcg/L of
aluminum.
Storage Store at 20 to 25°C
(68 to 77°F).
Store between 15 and 30°C. Store at 2°C to 8°C (36°F to
46°F); After dilution, the solu-
tion is stable for 48 hours
under refrigeration at 2°C to
8°C (36°F to 46°F) or at room
temperature from 20°C to
25°C (68°F to 77°F)
WAC Price 15 mL $14.57 5 mL $14.8115 mL $30.2850 mL $67.27
15 mL $13.10
* All trademarks mentioned herein are the exclusive property of their respective owners.
FDA Approved
Low Price
Lower Aluminum
Consistent Supply
short lip glues here
short lip glues here
Inside centerInside left
Pocket folds over to glue on this side
Inside pocket back
Inside pocket front
Insert 1Trim size: 8 x 5.25
Flat Size: TBD—
(Do Not Hold Die-line)
See page 5 for Important Safety Information
NOW AVAILABLE
The First FDA-ApprovedPotassium Phosphates Injectable
FIRST FDA APPROVED!FIRST FDA APPROVED!
P H A R M A
Exclusively from
P H A R M A
Exclusively from
Important Safety Information
INDICATIONS AND USAGEPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source
of phosphorus:
– in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of
age and older when oral or enteral replacement is not possible, insufficient or contraindicated.
– for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age
and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or
contraindicated.
• Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing
less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due
to the risk of aluminum toxicity.
CONTRAINDICATIONS– hyperkalemia
– hyperphosphatemia
– hypercalcemia or significant hypocalcemia
– severe renal impairment (eGFR less than 30 mL/min/1.73m2) and end stage renal disease
WARNINGS AND PRECAUTIONS– Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration:
Administer only after dilution or admixing; do not exceed the recommended infusion rate. Con-
tinuous electrocardiographic (ECG) monitoring may be needed during infusion.
– Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress
occur, stop the infusion and initiate a medical evaluation.
– Hyperkalemia: Increased risk in patients with renal impairment, severe adrenal insufficiency, or
treated with drugs that increase potassium. Patients with cardiac disease may be more suscepti-
ble. Do not exceed the maximum daily amount of potassium or the recommended infusion rate.
Continuous ECG monitoring may be needed during infusion.
– Hyperphosphatemia and Hypocalcemia: Monitor serum phosphorus and calcium concentra-
tions during and following infusion.
– Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.
– Hypomagnesemia: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor
serum magnesium concentrations during treatment.
– Vein Damage and Thrombosis: Infuse concentrated or hypertonic solutions through a central
catheter.
DRUG INTERACTIONSUse of Other Medications that Increase Potassium: Avoid use in patients receiving such products. If
use cannot be avoided, closely monitor serum potassium concentrations.
DOSAGE AND ADMINISTRATION– Administer intravenously only after dilution or admixing in a larger volume of fluid.
– POTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/
mL).
– Monitor serum phosphorus, potassium, calcium, and magnesium concentrations.
– See full prescribing information for instructions on preparation and administration.
ADVERSE REACTIONSAdverse reactions are hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia.
To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
PotassiumPHOSPHATESI N J E C T I O N
PotassiumPHOSPHATESI N J E C T I O N
Please see Full Prescribing Information in pocket for additional safety information
PPH-00001
It’s the first FDA-approved formulation available Currently, there is no other potassium phosphates injections formulation available that has been
approved by the FDA.
Market friendly price Competitively priced to ensure physicians have the choice to prescribe cost effective solutions
to their patients.
It addresses concerns from previous shortages of potassium phosphatesThe current phosphate repletion treatment market is strained due to previous shortages from
unapproved versions. Potassium Phosphates Injection helps alleviate these shortages by providing
a consistent supply of an FDA-approved formulation.
Current formulations have high aluminum contentCurrent unapproved formulations have higher aluminum content. Potassium Phosphates Injection
from CMP Pharma is a safe and consistent choice for healthcare professionals working with phosphate
replacement providing lower aluminum levels than current formulations.
Potassium Phosphates Injection is indicated as a source of phosphorus in intravenous fluids to correct
hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral
replacement is not possible, insufficient or contraindicated. Additionally, it is indicated as an additive
for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by
standard electrolyte or nutrient solutions.
CMP Potassium Phosphates Injection is now availablefrom national and regional wholesalers. For more information, contact
CMP Pharma at 252-753-7111.
Why Potassium Phosphates Injection from CMP Pharma?
FDA Approved
Low Price
Lower Aluminum
Consistent Supply
NOW AVAILABLE
The First FDA-ApprovedPotassium Phosphates Injectable
FIRST FDA APPROVED!FIRST FDA APPROVED!
P H A R M A
Exclusively from
P H A R M A
Exclusively from
Important Safety Information
INDICATIONS AND USAGEPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source
of phosphorus:
– in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of
age and older when oral or enteral replacement is not possible, insufficient or contraindicated.
– for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age
and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or
contraindicated.
• Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing
less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due
to the risk of aluminum toxicity.
CONTRAINDICATIONS– hyperkalemia
– hyperphosphatemia
– hypercalcemia or significant hypocalcemia
– severe renal impairment (eGFR less than 30 mL/min/1.73m2) and end stage renal disease
WARNINGS AND PRECAUTIONS– Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration:
Administer only after dilution or admixing; do not exceed the recommended infusion rate. Con-
tinuous electrocardiographic (ECG) monitoring may be needed during infusion.
– Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress
occur, stop the infusion and initiate a medical evaluation.
– Hyperkalemia: Increased risk in patients with renal impairment, severe adrenal insufficiency, or
treated with drugs that increase potassium. Patients with cardiac disease may be more suscepti-
ble. Do not exceed the maximum daily amount of potassium or the recommended infusion rate.
Continuous ECG monitoring may be needed during infusion.
– Hyperphosphatemia and Hypocalcemia: Monitor serum phosphorus and calcium concentra-
tions during and following infusion.
– Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.
– Hypomagnesemia: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor
serum magnesium concentrations during treatment.
– Vein Damage and Thrombosis: Infuse concentrated or hypertonic solutions through a central
catheter.
DRUG INTERACTIONSUse of Other Medications that Increase Potassium: Avoid use in patients receiving such products. If
use cannot be avoided, closely monitor serum potassium concentrations.
DOSAGE AND ADMINISTRATION– Administer intravenously only after dilution or admixing in a larger volume of fluid.
– POTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/
mL).
– Monitor serum phosphorus, potassium, calcium, and magnesium concentrations.
– See full prescribing information for instructions on preparation and administration.
ADVERSE REACTIONSAdverse reactions are hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia.
To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
PotassiumPHOSPHATESI N J E C T I O N
PotassiumPHOSPHATESI N J E C T I O N
Please see Full Prescribing Information in pocket for additional safety information
PPH-00001
It’s the first FDA-approved formulation available Currently, there is no other potassium phosphates injections formulation available that has been
approved by the FDA.
Market friendly price Competitively priced to ensure physicians have the choice to prescribe cost effective solutions
to their patients.
It addresses concerns from previous shortages of potassium phosphatesThe current phosphate repletion treatment market is strained due to previous shortages from
unapproved versions. Potassium Phosphates Injection helps alleviate these shortages by providing
a consistent supply of an FDA-approved formulation.
Current formulations have high aluminum contentCurrent unapproved formulations have higher aluminum content. Potassium Phosphates Injection
from CMP Pharma is a safe and consistent choice for healthcare professionals working with phosphate
replacement providing lower aluminum levels than current formulations.
Potassium Phosphates Injection is indicated as a source of phosphorus in intravenous fluids to correct
hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral
replacement is not possible, insufficient or contraindicated. Additionally, it is indicated as an additive
for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by
standard electrolyte or nutrient solutions.
CMP Potassium Phosphates Injection is now availablefrom national and regional wholesalers. For more information, contact
CMP Pharma at 252-753-7111.
Why Potassium Phosphates Injection from CMP Pharma?
FDA Approved
Low Price
Lower Aluminum
Consistent Supply
Inside right (full spread) Inside right (2-panel spread) Outside frontOutside back